CAR-T Cell Therapy for Solid Tumors: Are we Still That Far? a Systematic Review of Literature.
Auteurs : Karam A, Mjaess G, Martinez Chanza N, Aoun F, Bou Kheir G, Younes H, Kazzi H, Albisinni S, Roumeguère T Jaar : 2022 Journal : Cancer Invest
<sup>68</sup>Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy.
Auteurs : Shagera QA, Artigas C, Karfis I, Critchi G, Martinez Chanza N, Sideris S, Peltier A, Paesmans M, Gil T, Flamen P Jaar : 2021 Journal : J Nucl Med
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
Auteurs : Martinez Chanza N, Soukane L, Barthelemy P, Carnot A, Gil T, Casert V, Vanhaudenarde V, Sautois B, Staudacher L, Van Den Brande J, Culine S, Seront E, Gizzi M, Albisinni S, Tricard T, Fantoni JC, Paesmans M, Caparica R, Roumeguere T, Awada A Jaar : 2021 Journal : BMC Cancer
Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era.
Auteurs : Albisinni S, Martinez Chanza N, Aoun F, Diamand R, Mjaess G, Azzo JM, Esperto F, Bellmunt J, Roumeguère T, DE Nunzio C Jaar : 2021 Journal : Minerva Urol Nephrol
Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.
Auteurs : Martinez Chanza N, Bernard B, Barthelemy P, Accarain A, Paesmans M, Desmyter L, Tkint de Roodenbeke D, Gil T, Sideris S, Roumeguere T, Hamid AA, Sweeney CJ Jaar : 2021 Journal : Prostate Cancer Prostatic Dis